From Ejection Fraction to Fibrosis Phenotyping: Rethinking ICD Selection in Non-Ischemic Cardiomyopathy

Take home messages

• Risk stratification for sudden cardiac death in non-ischemic cardiomyopathy remains challenging as left ventricular ejection fraction alone is an inadequate predictor of arrhythmic risk.

• The fibrosis entropy study utilised cardiovascular magnetic resonance to assess myocardial fibrosis and introduced fibrosis entropy, a novel metric quantifying the heterogeneity of scar tissue.

• Higher fibrosis entropy was independently associated with life-threatening ventricular arrhythmias and provided incremental prognostic value beyond conventional risk markers such as ejection fraction and overall scar burden.

• These findings suggest that scar heterogeneity may be an important determinant of arrhythmogenic risk and highlight the role of advanced CMR phenotyping to guide decision-making of device implantation in heart failure

Prevention of sudden cardiac death (SCD) remains one of the central challenges in contemporary heart failure management (1). In patients with non-ischemic cardiomyopathy (NICM), SCD accounts for up to one-third of all deaths after presentation (2). Current recommendations for primary prevention implantable cardioverter‑defibrillator (ICD) implantation have traditionally been guided primarily by left ventricular ejection fraction (LVEF), which is an imperfect surrogate for predicting SCD risk in NICM (3). Many patients with severe systolic dysfunction will never experience malignant ventricular arrhythmias (VA), while others with only modest reductions in LVEF may succumb to SCD (4).

 

The DANISH trial sough to address this uncertainty and despite its limitation, it demonstrated that ICD implantation in NICM significantly reduced SCD but failed to improve overall mortality in those receiving contemporary medical therapy (5). This emphasized the need for better arrhythmic risk stratification beyond LVEF alone (4).

Author

  • Sub-editor:

    Dr Tha Htet Nyi is a cardiology registrar in South London Deanery with subspecialty interests in multimodal cardiac imaging and heart failure. He is currently undertaking a PhD in cardio-rheumatology at the Queen Mary University of London, funded by the NIHR Barts Biomedical Research Centre and Barts Charity. He graduated from the University of Medicine (1) in Myanmar in 2017, and completed internal medicine training in the East of England Deanery. He also holds a funded PG Certificate in Medical Education from the University of Bedfordshire. His doctoral research focuses on cardiac complications in autoimmune rheumatic diseases to improve early detection of heart failure and patient outcomes.

Related articles